Natural History of Sensorineural Hearing Loss in Children With STRC Mutations.

Chan, Kenny H; Nightengale, Emily E; Ekhteraei, Setareh; Schicke, Ericka; Tong, Suhong; Zhu, Austin; Burton, Barbara K · Laryngoscope · 2026

retrospective_cohort · Level III

Where this comes from

Abstract

The most common genes responsible for autosomal recessive nonsyndromic hearing loss (AR-NSHL) are GJB2 and STRC. STRC mutations are associated with mild-to-moderate sensorineural (SNHL) hearing loss and a lack of progression. However, our institutional experience suggested otherwise, prompting this review. A 10-year retrospective chart review was performed at a tertiary children's hospital after the University of Iowa added STRC to its OtoSCOPE<sup>R</sup> panel in 2013. Subjects with positive OtoSCOPE<sup>R</sup> results underwent audiologic review. Hearing progression was defined based on pure-tone average changes, and mutation subtypes were categorized. Of 354 subjects undergoing OtoSCOPE<sup>R</sup> testing, 181 (51.1%) carried a pathogenic mutation; GJB2 (28.7%) and STRC (16.6%) were most common. The STRC cohort included 30 subjects (21 males, 9 females) with hearing loss severity classifiable in 26 subjects and the highest proportion in the mild-to-moderate range (n = 46 ears; 88.5%). Hearing progression was observed in 12/24 subjects (20 ears: 8 bilateral, 4 unilateral). Median annual progression was 1.1 dB (range -3.5 to 18.7 dB). Two STRC subjects had substantial progression requiring cochlear implantation (one performed, one recommended). Genetic subtyping revealed seven categories, including six males with STRC/CATSPER2 deletions (deafness-infertility syndrome). No association between subtype and severity or progression was identified. STRC is the second most common cause of childhood NSHL and the leading contributor to mild-to-moderate SNHL. Unlike most published literature, 50% of our STRC cohort exhibited progression, and 17.6% of progressing subjects had substantial unilateral loss. We recommend long-term audiometric monitoring and standardized genomic reporting for this population.